LUNGevity Foundation, the nation's leading lung cancer nonprofit, applauds the Food and Drug Administration's approval of Bristol Myers Squibb's new immunotherapy drug Opdivo (nivolumab). Opdivo and other immunotherapy treatments add another critical new treatment option to fight lung cancer by harnessing the power of a patient's own immune system to fight cancerous cells.
from The Medical News http://ift.tt/1Nl7B4J
from The Medical News http://ift.tt/1Nl7B4J
No comments:
Post a Comment